| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial V Heinemann, LF von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, ... The lancet oncology 15 (10), 1065-1075, 2014 | 2035 | 2014 |
| Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ... JAMA oncology 3 (2), 194-201, 2017 | 817 | 2017 |
| The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials JW Holch, I Ricard, S Stintzing, DP Modest, V Heinemann European Journal of Cancer 70, 87-98, 2017 | 610 | 2017 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of … S Stintzing, DP Modest, L Rossius, MM Lerch, LF von Weikersthal, ... The Lancet Oncology 17 (10), 1426-1434, 2016 | 489 | 2016 |
| Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR V Heinemann, S Stintzing, T Kirchner, S Boeck, A Jung Cancer treatment reviews 35 (3), 262-271, 2009 | 361 | 2009 |
| Management of colorectal cancer S Stintzing F1000prime reports 6, 2014 | 357 | 2014 |
| Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO … DP Modest, I Ricard, V Heinemann, S Hegewisch-Becker, W Schmiegel, ... Annals of Oncology 27 (9), 1746-1753, 2016 | 327 | 2016 |
| Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes S Stintzing, S Tejpar, P Gibbs, L Thiebach, HJ Lenz European Journal of Cancer 84, 69-80, 2017 | 317 | 2017 |
| Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) V Heinemann, S Stintzing, DP Modest, C Giessen-Jung, M Michl, ... European journal of cancer 51 (14), 1927-1936, 2015 | 201 | 2015 |
| Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial S Stintzing, P Wirapati, HJ Lenz, D Neureiter, LF Von Weikersthal, ... Annals of Oncology 30 (11), 1796-1803, 2019 | 199 | 2019 |
| Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon … S Stintzing, A Jung, L Rossius, DP Modest, LF von Weikersthal, T Decker, ... European Journal of Cancer 49, S8-S9, 2013 | 183 | 2013 |
| Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors J García-Foncillas, Y Sunakawa, D Aderka, Z Wainberg, P Ronga, ... Frontiers in oncology 9, 849, 2019 | 180 | 2019 |
| Novel common genetic susceptibility loci for colorectal cancer SL Schmit, CK Edlund, FR Schumacher, J Gong, TA Harrison, JR Huyghe, ... JNCI: Journal of the National Cancer Institute 111 (2), 146-157, 2019 | 177 | 2019 |
| TAS-102, a novel antitumor agent: a review of the mechanism of action HJ Lenz, S Stintzing, F Loupakis Cancer treatment reviews 41 (9), 777-783, 2015 | 163 | 2015 |
| Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors … DP Modest, S Stintzing, LF von Weikersthal, T Decker, A Kiani, ... Journal of Clinical Oncology 33 (32), 3718-3726, 2015 | 154 | 2015 |
| Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study S Stintzing, L Miller-Phillips, DP Modest, LF von Weikersthal, T Decker, ... European Journal of Cancer 79, 50-60, 2017 | 153 | 2017 |
| Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab … JC Von Einem, V Heinemann, LF von Weikersthal, U Vehling-Kaiser, ... Journal of cancer research and clinical oncology 140, 1607-1614, 2014 | 151 | 2014 |
| Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK … V Heinemann, L Fischer von Weikersthal, T Decker, A Kiani, ... Journal of Clinical Oncology 31 (18_suppl), LBA3506-LBA3506, 2013 | 149 | 2013 |
| Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO … N Moosmann, LF von Weikersthal, U Vehling-Kaiser, M Stauch, HG Hass, ... Journal of clinical oncology 29 (8), 1050-1058, 2011 | 147 | 2011 |
| N eo FLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response … C Schulz, F Kullmann, V Kunzmann, M Fuchs, M Geissler, ... International journal of cancer 137 (3), 678-685, 2015 | 146 | 2015 |
Heinz-Josef LenzUniversity of Southern Califfornia在 usc.edu 的电子邮件经过验证
